An observational study in Coronary Chronic Total Occlusion and Coronary Artery Disease, sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Coronary Artery Disease by Assiut University — 12 open to participants now, 12 under way, none of them phase 3. Coronary Artery Disease · Assiut University.
Among the 27 studies in Coronary Artery Disease by Assiut University, this one is the 4th largest by planned enrollment of the 19 observational ones that give a count, is one of 2 that started in 2027, is one of 19 observational ones, reaches primary completion later than 11 of the 11 other live ones, and was the 27th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
Browse Coronary Artery Disease studies →12 of the 27 studies in Coronary Artery Disease by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University
Ages 18+
Assiut University · Sites in Egypt
Ages 18+
Assiut University
Ages 18+
Assiut University
Ages 18–50 · Men only
Assiut University
Ages 18–65
By country, each count listing its studies:
Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2027.
This study's planned enrollment of 160 is below the median of 326 across 1,689 observational studies indexed under Coronary Artery Disease.
Median enrollment 100 across the 8 interventional studies, 112 across the 19 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,188 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Coronary Artery Disease by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07860086Assiut UniversityOn vs Off-hour PPCI in STEMI Patients | 2027-06-30 |
| NCT07197242Assiut UniversityPrognostic Role of Lipoprotein(a) in Elective Percutaneous Coronary Revascularization | 2027-06-30 |
| NCT07847112Assiut UniversitySoluble TREM-1 in Diabetes-Associated Cardiovascular Complications | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 27 studies in Coronary Artery Disease by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will compare changes in the function of the right side of the heart after successful treatment of a long-standing complete blockage in either the right coronary artery or the left circumflex coronary artery. Patients will receive catheter-based treatment because their clinical team has independently decided that it is appropriate; the study will not assign their artery or treatment technique.
The planned comparison includes 160 patients with successful treatment, with 80 in each artery group. Heart ultrasound will be performed within 14 days before the procedure and again six months afterward. A telephone follow-up will take place at three months. Conventional ultrasound measurements and speckle tracking, which measures deformation of the heart muscle, will be used to assess right ventricular function. The main comparison is the change in right ventricular free-wall longitudinal strain between the two groups.
Design and setting:
Prospective, single-centre observational cohort at Assiut University Heart Hospital, with consecutive recruitment within two prespecified vessel strata. Elective percutaneous coronary intervention (PCI) is selected independently of research participation. The operator determines the clinical PCI technique. No research treatment assignment, stress test, additional catheterization, experimental drug, biomarker assay or SAQ-7 questionnaire is required.
Cohort formation:
Baseline written consent and research echocardiography precede PCI. The main comparison comprises technically successful index procedures: residual stenosis less than 30% with final TIMI 3 flow. One index attempt per patient defines cohort entry. Unsuccessful procedures are recorded descriptively in the screening log and do not contribute to the primary successful-procedure comparison. Procedural complications do not retrospectively redefine technical success. The planned main cohort is 80 RCA and 80 LCX patients; this is distinct from the number of patients screened or consented before PCI.
Recruitment schedule:
Anticipated recruitment is from 1 January 2027 through 30 June 2028. Each participant is followed for six months after index PCI, with the specified visit window. Recruitment end is distinct from final outcome collection.
Assessments:
Baseline clinical and resting echo assessment occurs within 14 days before PCI; repeat baseline if an intervening acute event occurs. Angiographic anatomy, procedure strategy, result, complications and discharge treatment are recorded at the index admission. Three-month telephone contact, with a 14-day window, records vital status, symptoms, admissions and medication changes and reminds participants of the six-month visit. Six-month resting echo and clinical reassessment allow a 30-day window. Late assessments are retained for sensitivity analysis.
Imaging:
Conventional two-dimensional echocardiography and RV speckle tracking are performed using a Philips system with AutoStrain RV, after verification of installed software, native RVFWSL/RV4CSL outputs and image export. Manufacturer, model and software version are documented. An RV-focused apical four-chamber view is acquired, with at least three stable ECG-linked cycles. Patient-level outputs are averaged across three acceptable cycles. Native global free-wall strain is the primary measure; four-chamber strain includes the septum. Signed source values are preserved. Images with persistent tracking failure are not replaced by another endpoint. Conventional measurements include FAC, TAPSE, tissue-Doppler S-prime and RV basal diameter. LVEF, LV volumes, valve regurgitation, E/e-prime and estimated pulmonary artery systolic pressure provide clinical context. PASP is recorded only when technically measurable.
Anatomical characterization:
Coronary dominance, CTO location relative to major branches, previous target-territory infarction, collateral supply, residual coronary disease and J-CTO score are recorded. All dominance patterns are eligible. The LCX cohort is a disease comparator, not a healthy control.
Sample-size rationale:
The target of 160 successful cases uses assumed planning inputs: a 2-percentage-point between-group difference in individual strain magnitude change, a common change SD of 4 points, two-sided alpha 0.05 and 80% power. A noncentral-t calculation requires 64 complete patients per group, increased to 80 per group for 20% incomplete paired assessment. These assumptions are not direct RCA-versus-LCX effect estimates or established minimal clinically important differences. At an assumed 85% success rate, approximately 95 eligible attempts per vessel stratum may be needed; this is a planning estimate rather than observed local recruitment data.
Analysis:
The primary endpoint is compared using a two-sided Welch t test with a 95% confidence interval. Supportive ANCOVA models six-month strain magnitude with vessel group, baseline strain magnitude, baseline LVEF, age, prior myocardial infarction and coronary dominance. The primary complete-pair estimand concerns survivors with successful index PCI and interpretable baseline and follow-up imaging. Deaths, failed procedures, withdrawals and tracking failures are reported separately; post-death strain is not imputed. Missing survivor outcomes are addressed by multiple imputation when feasible and sensitivity analyses. Signed-strain analysis, patient-level bootstrap intervals and analysis excluding major interval events are prespecified sensitivity checks. Formal secondary testing of RV4CSL, FAC, TAPSE and S-prime uses Holm correction. Segmental strain and symptom analyses are exploratory. Clinical events are descriptive; the study is not powered for mortality or major cardiovascular events and does not establish a causal effect of PCI.
Quality and ethics:
A separate technical run-in of 10-15 cases checks acquisition and analysis feasibility. Twenty-five paired examinations are randomly selected for interobserver and intraobserver repeat analysis; readers are blinded to group and visit order where feasible. Written consent and required institutional and ethics approvals precede research procedures. Coded records and image files are stored securely with the identity key separately. Clinical care remains independent of participation.
Clinically stable adults attending Assiut University Heart Hospital with one native RCA or LCX chronic total occlusion and an independently established clinical indication for elective PCI. Consecutive eligible patients are assessed within each vessel stratum. The main comparison targets 80 technically successful index procedures in each group. Consent and baseline research imaging precede PCI; unsuccessful index procedures are recorded descriptively outside the main comparative cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No arbitrary threshold is imposed. All coronary dominance patterns are eligible. Interval clinical deterioration, target-vessel failure, medication changes or clinically required subsequent revascularization do not retrospectively exclude an enrolled patient; they are recorded and follow-up is retained whenever possible.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with one native right coronary artery chronic total occlusion undergoing clinically indicated elective PCI with residual stenosis less than 30% and final TIMI 3 flow. Target: 80 technically successful patients. Baseline and six-month conventional and speckle tracking echocardiography are compared. Clinical treatment is not assigned by the research protocol.
Procedure: Clinically indicated RCA CTO PCI · Procedure: Resting conventional and RV speckle tracking echocardiography
Adults with one native left circumflex coronary artery chronic total occlusion undergoing clinically indicated elective PCI with residual stenosis less than 30% and final TIMI 3 flow. Target: 80 technically successful patients. Baseline and six-month conventional and speckle tracking echocardiography are compared. Clinical treatment is not assigned by the research protocol.
Procedure: Clinically indicated LCX CTO PCI · Procedure: Resting conventional and RV speckle tracking echocardiography
Elective PCI of a right coronary artery chronic total occlusion. The treating team selects the indication and technique independently of the research protocol; this is the observed clinical exposure.
Elective PCI of a left circumflex coronary artery chronic total occlusion. The treating team selects the indication and technique independently of the research protocol; this is the observed clinical exposure.
Resting ultrasound assessment within 14 days before index PCI and at six months, with a 30-day follow-up window. Includes RV free-wall and four-chamber strain and conventional RV measures. No stress test is required.
Change in right ventricular free-wall longitudinal strain magnitude
Individual change is the absolute magnitude of six-month RV free-wall longitudinal strain minus its baseline absolute magnitude, measured in percentage points. Native Philips RVFWSL output is used and signed source values are retained. A positive magnitude change denotes greater systolic shortening. The primary comparison is the difference in mean individual change between the RCA and LCX cohorts. For illustration only, a change from -20% to -23% equals +3 percentage points in magnitude; this is not an observed result or the assumed between-group effect.
Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in right ventricular four-chamber longitudinal strain magnitude
Change in native RV4CSL magnitude, including free wall and septum, from baseline to six months, in percentage points. Positive change denotes greater shortening magnitude; signed source values are preserved.
Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in right ventricular fractional area change
Six-month minus baseline RV fractional area change (FAC), in percentage points. FAC is 100 times (end-diastolic area minus end-systolic area) divided by end-diastolic area in an RV-focused view.
Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in tricuspid annular plane systolic excursion
Six-month minus baseline TAPSE, in millimetres, measured by aligned M-mode at the lateral tricuspid annulus.
Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in tricuspid annular systolic tissue-Doppler velocity
Six-month minus baseline systolic S-prime velocity, in centimetres per second, measured by pulsed tissue Doppler at the lateral tricuspid annulus.
Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in right ventricular basal diameter
Six-month minus baseline RV basal diameter, in millimetres, measured in the RV-focused apical four-chamber view.
Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in Canadian Cardiovascular Society angina class
Baseline and six-month CCS angina class and individual class transitions are recorded. Classes I through IV indicate progressively greater limitation by angina; a lower class denotes improvement. This is an exploratory clinical secondary outcome.
Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in New York Heart Association functional class
Baseline and six-month NYHA functional class and individual class transitions are recorded. Classes I through IV indicate progressively greater functional limitation; a lower class denotes improvement. This is an exploratory clinical secondary outcome.
Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in basal right ventricular free-wall segmental longitudinal strain magnitude
Exploratory six-month minus baseline magnitude change in basal RV free-wall peak systolic longitudinal strain, in percentage points, when supported by the installed software and acceptable tracking. Settings remain consistent across visits. Signed values are retained. Segments are not treated as independent patients.
Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in mid right ventricular free-wall segmental longitudinal strain magnitude
Exploratory six-month minus baseline magnitude change in mid RV free-wall peak systolic longitudinal strain, in percentage points, when supported by the installed software and acceptable tracking. Settings remain consistent across visits. Signed values are retained. Segments are not treated as independent patients.
Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in apical right ventricular free-wall segmental longitudinal strain magnitude
Exploratory six-month minus baseline magnitude change in apical RV free-wall peak systolic longitudinal strain, in percentage points, when supported by the installed software and acceptable tracking. Settings remain consistent across visits. Signed values are retained. Segments are not treated as independent patients.
Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Plan to share: No — The IPD might not be shared according to the local institutional policy.
Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.
Of 636 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 24 months is below that.
Counting every sponsor, half of 761 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.